Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $326,520.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,721 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the sale, the senior vice president owned 3,114 shares in the company, valued at $373,680. This trade represents a 46.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total value of $264,458.30.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $125.59 on Friday. Mirum Pharmaceuticals, Inc. has a 52 week low of $49.01 and a 52 week high of $125.75. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The company’s fifty day moving average is $103.20 and its 200-day moving average is $95.77. The company has a market capitalization of $7.66 billion, a PE ratio of -9.23 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. During the same quarter last year, the business earned ($0.30) EPS. The company’s revenue for the quarter was up 43.3% compared to the same quarter last year. Equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cullen Frost Bankers Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $30,000. Eurizon Capital SGR S.p.A. bought a new stake in Mirum Pharmaceuticals in the fourth quarter valued at approximately $32,000. CIBC Private Wealth Group LLC acquired a new stake in Mirum Pharmaceuticals in the fourth quarter worth $32,000. Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals during the third quarter worth $33,000. Finally, Comerica Bank grew its holdings in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MIRM. Royal Bank Of Canada boosted their target price on Mirum Pharmaceuticals from $128.00 to $142.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. TD Cowen raised their price target on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. lifted their price objective on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. Finally, Robert W. Baird raised their target price on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $143.00.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.